TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 15380897
Drug: Probiotic Lactobacillus
Normalized name: Probiotic Lactobacillus Acidophilus Caplets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic Lactobacillus plantarum 299v (ProViva), median volume 3250 ml, median duration 9 days
Study: 8540748
Drug: Ascoxal (ascorbic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ascoxal (ascorbic acid-containing solution), applied topically 3 times for 2 min on the first day
Study: 2551988
Drug: Captopril 25
Normalized name: captopril 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril 25 mg b.i.d. + Indomethacin 50 mg b.i.d.
Study: 2551988
Drug: Enalapril 20
Normalized name: enalapril 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril 20 mg o.i.d. + Indomethacin 50 mg b.i.d.
Study: 7562679
Drug: Captopril 25
Normalized name: captopril 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril 25 mg b.i.d.
Study: 2551988
Drug: Enalapril 20
Normalized name: enalapril 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril 20 mg o.i.d.
Study: 2551988
Drug: Captopril 25
Normalized name: captopril 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril 25 mg b.i.d. and Enalapril 20 mg o.i.d.
Study: 1381763
Drug: Indomethacin 50
Normalized name: indomethacin 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indomethacin 50 mg b.i.d.
Study: 749190
Drug: Adjuvant chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant chemotherapy added to radical mastectomy
Study: 749190
Drug: Combination chemo-
Normalized name: Chem-Star Recover
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination chemo- or chemo-hormono-therapy
Study: 749190
Drug: Local therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local therapy alone (surgery with or without postoperative radiotherapy)
Study: 23233269
Drug: Oxytocin intranasal
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oxytocin intranasal spray (20 IU twice a day for the first week, then 40 IU twice a day for the following 7 weeks)
Study: 23233269
Drug: Oxytocin intranasal
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oxytocin intranasal spray
Study: 23233269
Drug: Placebo intranasal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo intranasal spray (normal saline)
Study: 15056124
Drug: HCA-SX 4667
Normalized name: SX-682
DrugBank: SX-682 (DB19210)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HCA-SX 4667 mg
Study: 15056124
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of HCA-SX 4667 mg, NBC 4 mg, and GSE 400 mg
Study: 11763951
Drug: 1.25 g
Normalized name: AndroGel 1.25 g Packets
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.25 g dentifrice containing 0.3% triclosan (3.75 mg triclosan dose) - single-dose phase
Study: 11763951
Drug: Three times
Normalized name: WELLBUTRIN 100 MG Oral Tablet, Three Times Daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three times daily brushing with 1.25 g dentifrice containing 0.3% triclosan - multiple-dose phase
Study: 11763951
Drug: Twice daily
Normalized name: CAPSULE, TWICE DAILY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice daily brushing with 1 gm of dentifrice containing 0.2% triclosan
Study: 9574192
Drug: Antibiotic carrier
Normalized name: Valiant Barrier
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic carrier (group 1)
Study: 9574192
Drug: No antibiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: No antibiotic carrier (group 2)
Study: 7840418
Drug: Ketamine 1.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine 1.3 mg/kg bolus + 4 mg/kg/h continuous for 15 min
Study: 7840418
Drug: S-(+)-ketamine 0.65
Approvals — FDA: no, EMA: no, PMDA: no
Description: S-(+)-ketamine 0.65 mg/kg bolus + 2 mg/kg/h continuous for 15 min
Study: 7840418
Drug: S-(+)-ketamine 0.65
Approvals — FDA: no, EMA: no, PMDA: no
Description: S-(+)-ketamine 0.65 mg/kg bolus + 2 mg/kg/h continuous for 15 min + physostigmine 0.012 mg/kg
Study: 7840418
Drug: S-(+)-ketamine 0.65
Approvals — FDA: no, EMA: no, PMDA: no
Description: S-(+)-ketamine 0.65 mg/kg bolus + 2 mg/kg/h continuous for 15 min + saline placebo
Study: 9356091
Drug: verapamil 0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: verapamil 0.1 mg/kg I.V. plus saline
Study: 9356091
Drug: lidocaine 1
Normalized name: lidocaine 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: lidocaine 1 mg/kg I.V. plus saline
Study: 9356091
Drug: verapamil 0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: verapamil 0.1 mg/kg I.V. plus lidocaine 1 mg/kg I.V.
Study: 3954370
Drug: High-dose metoclopramide
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose metoclopramide (2 mg/kg x 4: H)
Study: 3954370
Drug: Moderate-dose metoclopramide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderate-dose metoclopramide (1 mg/kg x 4: M)
Study: 28852716
Drug: Dry cupping
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dry cupping therapy
Study: 24808482
Drug: Weekly context-appropriate
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Weekly context-appropriate child-centered counseling (CCC)
Study: 21251896
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg of MET (n = 19) for 4 weeks followed by 100 mg MET for 4 weeks
Study: 21251896
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg of NEB (n = 22) for 4 weeks followed by 10 mg NEB for 4 weeks
Study: 16253414
Drug: Urapidil (initial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Urapidil (initial dose of 12.5-25mg)
Study: 16253414
Drug: Dihydralazine (uniform
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dihydralazine (uniform initial dose of 5mg)
Study: 14649341
Drug: Intraperitoneal bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraperitoneal bupivacaine 0.25% plus intravenous morphine 2 mg
Study: 9007717
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose UDCA (10 mg kg‐1 day‐1) at bed time
Study: 9007717
Drug: Multiple dose
Normalized name: Rebetron, multiple dose 600 mg/day oral and injectable kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple dose UDCA (10 mg kg‐1 day‐1) in three divided doses with meals
Study: 6751536
Drug: Fentiazac 100
Normalized name: fentiazac
DrugBank: Fentiazac (DB13217)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentiazac 100 mg four times a day for one week
Study: 31682976
Drug: Fosamprenavir administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fosamprenavir administered during MMC phase II
Study: 31682976
Drug: Fosamprenavir administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fosamprenavir administered during MMC phase I
Study: 22562389
Drug: Subcutaneous adalimumab
Normalized name: Adalimumab
DrugBank: Adalimumab (DB00051)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Subcutaneous adalimumab injections
Study: 22562389
Drug: Intraarticular glucocorticoid
Normalized name: dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intraarticular glucocorticoid injections
Study: 8172482
Drug: Bepridil (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bepridil (300 mg/day after a loading dose of 900 mg on D1, 500 mg on D2 and D3)
Study: 6851041
Drug: Diltiazem (360
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diltiazem (360 mg/day)
Study: 3075350
Drug: Mefloquine (750
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mefloquine (750 mg) and artemether (600 mg by injection, 200 mg initially and 100 mg every 12 h)
Study: 3075350
Drug: Quinine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quinine (10 mg/kg orally every 8 h for 7 d)
Study: 31470444
Drug: DAPT plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: DAPT plus high-dose edoxaban (60 mg once daily)
Study: 31470444
Drug: DAPT plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: DAPT plus low-dose edoxaban (30 mg once daily)
Study: 28827258
Drug: Faecal microbiota
Approvals — FDA: no, EMA: no, PMDA: no
Description: Faecal microbiota transplantation (FMT) administered via enema, two times per week for 6 weeks.
Study: 28827258
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline control administered via enema, two times per week for 6 weeks.
Study: 2185303
Drug: Milnacipran 200
Normalized name: MILNACIPRAN
DrugBank: Milnacipran (DB04896)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Milnacipran 200 mg/d
Study: 16634956
Drug: 800 mg
Normalized name: bran 800 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 800 mg ibuprofen arginine
Study: 8826510
Drug: Tenoxicam (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tenoxicam (20 mg) + bromazepan (3 mg)
Study: 8826510
Drug: Tenoxicam (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tenoxicam (20 mg) + placebo
Study: 8826510
Drug: Bromazepan (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bromazepan (3 mg) + placebo
Study: 6731021
Drug: Omnipaque 350
Normalized name: Omnipaque 350
DrugBank: Iohexol (DB01362)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Omnipaque 350 mg I/ml
Study: 6731021
Drug: Urografin 370
Normalized name: Urografin 370
Approvals — FDA: no, EMA: no, PMDA: no
Description: Urografin 370 mg I/ml
Study: 31126551
Drug: Urtica dioica
Normalized name: Urtica Dioica
Approvals — FDA: no, EMA: no, PMDA: no
Description: Urtica dioica 450 mg/day and acupuncture 11 sessions (A)
Study: 27601217
Drug: Placebo (dextrose,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (dextrose, same dosage)
Study: 24004044
Drug: Sensor-augmented insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sensor-augmented insulin pump (SAP)
Study: 21488717
Drug: Multiple daily
Normalized name: Multivitamin Oral Tablet [MULTIPLE DAILY W/BETA]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple daily injection (MDI) therapy
Study: 8831474
Drug: Local steroid
Normalized name: RECTAL,LOCAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local steroid injection plus elbow splinting (Group B)
Study: 1429485
Drug: Fluoxetine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine (20 mg/day, 40 mg/day, 60 mg/day)
Study: 4043661
Drug: Vancomycin (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vancomycin (500 mg/day)
Study: 30520413
Drug: Modified self‐management
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified self‐management plan advising temporary quadrupling of inhaled corticosteroid dose
Study: 20578203
Drug: Risk factors
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risk factors measured (elevated A(1c), 2‐h PG, fasting insulin (FI), albuminuria, obesity)
Study: 15921608
Drug: Typhoid Vi
Normalized name: Typhoid Vi polysaccharide vaccine
DrugBank: Typhoid Vi polysaccharide vaccine (DB10803)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Typhoid Vi vaccine
Study: 15921608
Drug: Meningococcal A
Normalized name: MENINGOCOCCAL A/B/C/W/Y (PENBRAYA) KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meningococcal A vaccine
Study: 11813173
Drug: Prophylactic G-CSF
Normalized name: G-CSF
DrugBank: Lenograstim (DB13144)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic G-CSF administration after chemotherapy intensification
Study: 10400415
Drug: GM‐CSF at
Approvals — FDA: no, EMA: no, PMDA: no
Description: GM‐CSF at a dose of 3 microg/kg s.c. on days 1‐2, rhEpo at a dose of 60 U/kg s.c. on days 3‐5, repeated for a total of 6 weeks, with dose increase to 120 U/kg if Hb rise not achieved.
Study: 7267677
Drug: Minaprine (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Minaprine (100 mg per day)
Study: 27697911
Drug: Alcohol treatment
Normalized name: Alcohol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alcohol treatment (intoxicated)
Study: 27484437
Drug: p-synephrine (S;
Approvals — FDA: no, EMA: no, PMDA: no
Description: p-synephrine (S; 100 mg)
Study: 27484437
Drug: p-synephrine +
Normalized name: synephrine
DrugBank: Synephrine (DB09203)
Approvals — FDA: no, EMA: no, PMDA: no
Description: p-synephrine + caffeine (SCF; 100 mg of p-synephrine plus 100 mg of caffeine)
Study: 23903811
Drug: Intrathecal morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathecal morphine dose reduction (20% reduction weekly for 10 weeks)
Study: 23903811
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no change in morphine dose)
Study: 19712598
Drug: Pharmaceutical intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pharmaceutical intervention programme
Study: 12435255
Drug: Ramipril (2.5‐10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ramipril (2.5‐10 mg/d)
Study: 12435255
Drug: Metoprolol (50‐200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol (50‐200 mg/d)
Study: 12435255
Drug: Amlodipine (5‐10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amlodipine (5‐10 mg/d)
Study: 10626558
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone (GH) treatment at a dose of 0.1 IU/kg/day (0.033 mg/kg/day) for 2 years (Group A)
Study: 10626558
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone (GH) treatment at a dose of 0.2 IU/kg/day (0.066 mg/kg/day) during the second year (Group B)
Study: 10626558
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone (GH) treatment restarted at a dose of 0.1 IU/kg/day (0.033 mg/kg/day) after a 6-month break
Study: 10626558
Drug: Not applicable
Normalized name: AIR 1000 mL in 1 L NOT APPLICABLE GAS
DrugBank: Urea (DB03904)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Not applicable (GH treatment withdrawn)
Study: 1951859
Drug: Oral metrifonate
Normalized name: Metrifonate
DrugBank: Metrifonate (DB11473)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral metrifonate (10 mg/kg for three doses each year)
Study: 1951859
Drug: Praziquantel therapy
Normalized name: Praziquantel
DrugBank: Praziquantel (DB01058)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Praziquantel therapy (40 mg/kg as a single dose each year)
Study: 7197489
Drug: Droperidol, 2.5
Normalized name: Droperidol, 2.5 mg/mL injectable solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Droperidol, 2.5 mg IM
Study: 7197489
Drug: Hydroxyzine, 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydroxyzine, 100 mg IM
Study: 29805252
Drug: Active buprenorphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active buprenorphine 5 µg/hour
Study: 28099979
Drug: Intravenous milrinone
Normalized name: Milrinone
DrugBank: Milrinone (DB00235)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous milrinone lactate (low dose: 20 mcg/kg bolus followed by 0.2 mcg/kg/minute)
Study: 28099979
Drug: Intravenous milrinone
Normalized name: Milrinone
DrugBank: Milrinone (DB00235)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous milrinone lactate (standard dose: 50 mcg/kg bolus followed by 0.5 mcg/kg/minute)
Study: 26268533
Drug: Agomelatine (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Agomelatine (25 mg)
Study: 16117817
Drug: Agomelatine (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Agomelatine (50 mg)
Study: 10405745
Drug: Injection of
Normalized name: purified protein derivative of tuberculin Injectable Solution [Aplisol]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection of 2 mL/kg of 300 mg iodine/mL contrast material at 5 mL/sec (Group 1)
Study: 10405745
Drug: Injection of
Normalized name: purified protein derivative of tuberculin Injectable Solution [Aplisol]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection of 2 mL/kg of 300 mg iodine/mL contrast material at 3 mL/sec (Group 2)
Study: 10405745
Drug: Injection of
Normalized name: purified protein derivative of tuberculin Injectable Solution [Aplisol]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection of 1.5 mL/kg of 300 mg iodine/mL contrast material at 5 mL/sec (Group 3)
Study: 10405745
Drug: Injection of
Normalized name: purified protein derivative of tuberculin Injectable Solution [Aplisol]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection of 1.5 mL/kg of 300 mg iodine/mL contrast material at 3 mL/sec (Group 4)
Study: 31811673
Drug: Ibuprofen plus
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ibuprofen plus acetaminophen
Study: 30955985
Drug: Ibuprofen plus
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ibuprofen plus placebo
Study: 28410922
Drug: Artichoke Leaf
Normalized name: artichoke leaf extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Artichoke Leaf Extract (ALE) 1800 mg (four tablets per day)
Study: 28410922
Drug: Placebo (cornstarch,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (cornstarch, lactose, and avicel, four tablets per day)
Study: 27681579
Drug: Dovitinib capsule
Normalized name: Dovitinib
DrugBank: Dovitinib (DB05928)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dovitinib capsule (500 mg once daily on a 5-days-on/2-days-off schedule)
Study: 27681579
Drug: Dovitinib tablet
Normalized name: Dovitinib
DrugBank: Dovitinib (DB05928)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dovitinib tablet (500 mg once daily on a 5-days-on/2-days-off schedule)
Study: 27681579
Drug: Dovitinib (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dovitinib (both formulations)
Study: 22154243
Drug: Monophasic preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monophasic preparation containing 30μg ethinylestradiol and 150μg desogestrel (DG/EE)
Study: 22154243
Drug: Monophasic preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monophasic preparation containing 30μg ethinylestradiol and 150μg levonogestrel (LNG/EE)
Study: 20223599
Drug: High-dose corticosteroid
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose corticosteroid therapy (methylprednisolone)
Study: 20223599
Drug: Alternative therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alternative therapy (mitoxantrone)
Study: 20223599
Drug: Major depression
Approvals — FDA: no, EMA: no, PMDA: no
Description: Major depression (MD) receiving antidepressants
Study: 15878492
Drug: Inhalation of
Normalized name: Ocean brand of sodium chloride Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhalation of thermal water (active group, n=20)
Study: 15878492
Drug: Inhalation of
Normalized name: Ocean brand of sodium chloride Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhalation of thermal water (active group)
Study: 10465168
Drug: n-3 polyunsaturated
Normalized name: Omega-3 (n-3) polyunsaturated fatty acids
Approvals — FDA: no, EMA: no, PMDA: no
Description: n-3 polyunsaturated fatty acids (1 g daily, n=2836)
Study: 10465168
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment (n-3 PUFA and vitamin E, n=2830)
Study: 10465168
Drug: Vitamin E
Normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vitamin E (300 mg daily, n=2830)
Study: 30527287
Drug: Polyherbal combination
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polyherbal combination tablets
Study: 30457892
Drug: Turmeric tablets
Normalized name: Nature's Way Turmeric Tablets
DrugBank: Turmeric (DB14276)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Turmeric tablets
Study: 28096034
Drug: Self-referral to
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-referral to inpatient treatment (SRIT) contract
Study: 22030384
Drug: Tibolone 2.5mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tibolone 2.5mg daily
Study: 19885409
Drug: Fluoride treatment
Normalized name: 60 Second 1.23% Fluoride Treatment Dental Gel
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fluoride treatment (FTB)
Study: 19885409
Drug: Titanium dioxide
Normalized name: Titanium Dioxide
DrugBank: Titanium dioxide (DB09536)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Titanium dioxide grit-blasted (TB) implants
Study: 11350556
Drug: Epinephrine irrigation
Normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Epinephrine irrigation (40‐120 mL of 1:1,000,000 epinephrine)
Study: 1841833
Drug: High-dose bovine
Normalized name: Pegademase Bovine
DrugBank: Pegademase (DB00061)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: High-dose bovine surfactant (100 mg/kg birth weight)
Study: 1841833
Drug: Low-dose bovine
Normalized name: Pegademase Bovine
DrugBank: Pegademase (DB00061)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Low-dose bovine surfactant (50 mg/kg birth weight)
Study: 3300375
Drug: Bromocriptine, 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bromocriptine, 2.5 mg twice daily
Study: 31306084
Drug: RTS,S/AS01 with
Approvals — FDA: no, EMA: no, PMDA: no
Description: RTS,S/AS01 with dihydroartemisinin-piperaquine plus a single low dose primaquine
Study: 31306084
Drug: RTS,S/AS01 without
Approvals — FDA: no, EMA: no, PMDA: no
Description: RTS,S/AS01 without antimalarial drugs
Study: 31306084
Drug: RTS,S/AS01 with
Approvals — FDA: no, EMA: no, PMDA: no
Description: RTS,S/AS01 with and without antimalarial drugs
Study: 25327812
Drug: Nemonoxacin (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nemonoxacin (500 mg) + Antacid (318 mg Al(3+) and 496 mg Mg(2+))
Study: 25327812
Drug: Nemonoxacin (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nemonoxacin (500 mg) + Antacid (4 hours after)
Study: 25327812
Drug: Nemonoxacin (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nemonoxacin (500 mg) + Antacid (2 hours before)
Study: 25327812
Drug: Nemonoxacin (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nemonoxacin (500 mg) + Ferrous sulfate (60 mg Fe(2+))
Study: 25327812
Drug: Nemonoxacin (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nemonoxacin (500 mg) + Calcium carbonate (600 mg Ca(2+))
Study: 25327812
Drug: Nemonoxacin (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nemonoxacin (500 mg) alone
Study: 20737683
Drug: INFLUVIR vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: INFLUVIR vaccine administered intranasally
Study: 20737683
Drug: PANDEFLU vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PANDEFLU vaccine administered intramuscularly
Study: 10714789
Drug: Newer antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Newer antibiotics (macrolides and quinolones)
Study: 10714789
Drug: Conventional antimicrobial
Normalized name: GAUZE,ANTIMICROBIAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional antimicrobial therapy (beta-lactam therapy)
Study: 1867232
Drug: Lovastatin 20
Normalized name: lovastatin 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lovastatin 20 mg/day